Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Adma Biologics (ADMA) EBT Margin (2016 - 2025)

Adma Biologics' EBT Margin history spans 13 years, with the latest figure at 44.26% for Q4 2025.

  • For Q4 2025, EBT Margin rose 1473.0% year-over-year to 44.26%; the TTM value through Dec 2025 reached 35.8%, up 632.0%, while the annual FY2025 figure was 35.8%, 632.0% up from the prior year.
  • EBT Margin reached 44.26% in Q4 2025 per ADMA's latest filing, up from 35.4% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 44.26% in Q4 2025 to a low of 114.26% in Q1 2021.
  • Average EBT Margin over 5 years is 11.21%, with a median of 4.13% recorded in 2023.
  • Peak YoY movement for EBT Margin: soared 11552bps in 2021, then tumbled -58bps in 2025.
  • A 5-year view of EBT Margin shows it stood at 30.01% in 2021, then grew by 21bps to 23.59% in 2022, then surged by 161bps to 14.33% in 2023, then soared by 106bps to 29.53% in 2024, then surged by 50bps to 44.26% in 2025.
  • Per Business Quant, the three most recent readings for ADMA's EBT Margin are 44.26% (Q4 2025), 35.4% (Q3 2025), and 32.87% (Q2 2025).